Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Awakn Life Sciences Corp (OP: AWKNF ) 0.0709 +0.0109 (+18.17%) Streaming Delayed Price Updated: 11:03 AM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Awakn Life Sciences Corp < Previous 1 2 3 4 5 Next > Investors Back Awakn's Psychedelic Therapies, As Company Doubles Private Placement To $2M September 18, 2024 Awakn Life Sciences expands its private placement to $2 million, closing the fourth tranche with $394,286 raised to accelerate research into addiction treatments. Via Benzinga Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More April 17, 2024 Via Benzinga Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More February 15, 2024 Via Benzinga Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More January 26, 2024 Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and online course available. Via Benzinga Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More December 27, 2023 President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also... Via Benzinga Awakn Life Sciences Enters Into Global Licensing Agreement For Sublingual Delivery Formulation December 21, 2023 Awakn Life Sciences (OTC: AWKNF), a clinical-stage biotechnology company specializing in the development of ketamine-assisted treatments for addiction, has enter Via Benzinga Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More November 24, 2023 GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan Via Benzinga Topics Cannabis Exposures Cannabis UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center November 15, 2023 The U.K. Medicines and Healthcare Regulatory Agency (MHRA) has green-lighted two separate Phase 3 trials conducted by Compass Pathways (NASDAQ: CMPS) for Treatment-Resistant Depression and Awakn Life... Via Benzinga U.K.'s Prof. David Nutt Ranked World's Top Psychopharmacologist: More On His Contributions & Advocacy October 15, 2023 Professor David Nutt, a cognitive sciences, addiction, cannabis and psychedelics researcher, has been ranked the #1 psychopharmacologist by ScholarGPS, a California-based American company owned and... Via Benzinga Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More September 11, 2023 Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence Awakn Life Sciences Submits CTA For Phase III Alcohol Use Disorder Clinical Trial September 06, 2023 Awakn Life Sciences Corp. (OTC: AWKNF), a biotech firm focused on developing therapies for addiction, with a primary emphasis on Alcohol Use Disorder (AUD), has taken a big step toward Phase III... Via Benzinga Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More August 14, 2023 First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published Via Benzinga Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More August 03, 2023 A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances... Via Benzinga Awakn Life Sciences Becomes Pure R&D Biotech After Sale Of Norway Clinics August 01, 2023 As part of its business restructuring process and following its London clinics busin Via Benzinga Awakn Life Sciences On Track With Phase 3 Trial To Research Substance Use Disorder July 26, 2023 On this new Psychedelics Exclusive podcast, TDR Founder Shadd Dales interviews Awakn Life Sciences Corp. (OTC: AWKNF) CEO Anthony Tennyson, as his company moves closer towards a Phase III clinical... Via Benzinga Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More July 11, 2023 First Country Allowing MDMA & Psilocybin For Depression, PTSD Makes Headlines On Saturday, July 1, 2023, Australia became the first country to allow physicians to prescribe MDMA to treat post-traumatic... Via Benzinga Awakn Life Sciences Sells London Clinics Business, Hopes To Divest Norwegian Unit Next July 05, 2023 Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) sold its London subsidiary and healthcare clinic. Via Benzinga Awakn Life Sciences Announces Closing Of Second Tranche And Upsizing Of Previous Private Placement June 15, 2023 UK-based psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) announced the closing of the second tranche of its latest non-brokered private placement as well as an upsizing of the original... Via Benzinga Awakn To Focus On R&D Of Addiction Therapies, Moves Away From Ketamine Treatment For Alcoholism June 12, 2023 Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) is set to exit ketamine healthcare services to focus solely on research and development of therapeutics to treat addiction and licensing of... Via Benzinga Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More May 01, 2023 Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued Via Benzinga Awakn's Q4 2023 And Annual Financials, +500% YoY Revenue Increase Following Network Expansion April 28, 2023 The UK-based psychedelics biotech company Awakn Life Sciences Corp. (OTCQB: AWKNF) reported on its financial results and business highlights for the three and twelve months ended Jan. 31, 2023. Via Benzinga Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More April 24, 2023 LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a... Via Benzinga Severe Alcohol Use Disorder Patients Will Try Ketamine Therapy At Awakn's New Phase 3 Study April 19, 2023 The research partnership between UK-based psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) and the University of Exeter for an upcoming Via Benzinga EXCLUSIVE: MDMA Therapy Experts Debate Upcoming Approval And Psychedelic Market Opps April 19, 2023 In the current psychedelics landscape, one of the most important topics is compound legality. While it's possible that MDMA-assisted therapy will eventually be federally approved in the U.S., what... Via Benzinga Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More April 17, 2023 Revolutionizing Psychedelics: 2 Industry Leaders Team Up On Clinical-Grade MDMA Capsules Via Benzinga Awakn's Psychedelics Medical Chief Steps Down, Shifts In Company's Stocks And Ownership April 14, 2023 Awakn Life Sciences Corp. (OTCQB: AWKNF), the biotech company developing psychedelic therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD) shared its recent corporate... Via Benzinga EXCLUSIVE: Ketamine Therapy Provider Nushama Co-Founder On Shifting From A Consciousness Of Blame Into A Space Of Responsibility March 19, 2023 In light of the latest news regarding the DEA’s telehealth regulations and the Via Benzinga Major Psychedelics VC & EFT Directors Will Share Valuable Insights At Upcoming Benzinga Event March 13, 2023 The Benzinga Psychedelics Capital Conference (PCC) is rapidly becoming the place to be for all those interested or involved in the space. In addition to being the place where deals are done, you'll... Via Benzinga Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More March 07, 2023 Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been... Via Benzinga MDMA News: Exclusive Supply Deal With Awakn Life Sciences & Canadian Company Expands Psychedelics Production March 02, 2023 PharmAla To Be Exclusive MDMA Supply Partner To Awakn Life Sciences Effective immediately, MDXX class molecules producer PharmAla Biotech Holdings Inc. will become the exclusive MDMA supplier to Awakn... Via Benzinga < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.